← Volver a la listaCompanyRudaCure actualmente está developing the eye drop RCI001 centered around Professor Donghyun Kim (Department of Ophthalmology, Gachon University). Dry eye disease — an uncomfortable condition for the eyes — is viewed as one type of trastorno sensorial. The tratamiento approach involves suppressing the abnormal signal transduction of Rac1, which is associated with the generation of reactive oxygen species and inflammatory responses, to treat enfermedad de ojo seco.
Some eye drops contain substances that stimulate pain nerves, causing discomfort upon instillation — this is a well-known drawback. RCI001 does not stimulate nerves, so it does not cause pain when applied. It also does not produce elevated presión intraocular, a efecto secundario that can lead to glaucoma.
RudaCure también developing RCI002, a non-narcotic tratamiento del dolor. Since the American Pain Society presentó for bankruptcy in 2019 after facing lawsuits for encouraging overprescription of analgésicos narcóticos, the desarrollo of analgésico no narcóticos has become a global priority. RCI002 reduces pain by inhibiting the function of TRPV1, a protein critical to pain signaling.
RudaCure is a growing company that is actively building asociacións with major empresas farmacéuticas. ← Volver a la lista
[Startups médicas] Abrazando incluso el dolor — una historia de pasión
2022-02-21
Some eye drops contain substances that stimulate pain nerves, causing discomfort upon instillation — this is a well-known drawback. RCI001 does not stimulate nerves, so it does not cause pain when applied. It also does not produce elevated presión intraocular, a efecto secundario that can lead to glaucoma.
RudaCure también developing RCI002, a non-narcotic tratamiento del dolor. Since the American Pain Society presentó for bankruptcy in 2019 after facing lawsuits for encouraging overprescription of analgésicos narcóticos, the desarrollo of analgésico no narcóticos has become a global priority. RCI002 reduces pain by inhibiting the function of TRPV1, a protein critical to pain signaling.
RudaCure is a growing company that is actively building asociacións with major empresas farmacéuticas.